.png){kind=icon}
.png){kind=icon}
Return
Tezepelumab Reverses TSLP-Driven Immunometabolic Rewiring in Human cDC2s Underlying Pathogenic Th2 and Dysfunctional Treg Responses
.png){kind=icon}
PRE
AI
L
A
I
A
S
Ó
DOI：10.1111/all.70470.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Thymic stromal lymphopoietin (TSLP) is a key epithelial alarmin involved in the initiation and maintenance of type 2 inflammatory airway diseases. Although tezepelumab, the first approved anti-TSLP monoclonal antibody, has shown robust clinical efficacy in asthma and CRSwNP, the molecular mechanisms underlying its mode of action remain incompletely defined.
Keywords:
asthma
cDC2s
chronic rhinosinusitis with nasal polyps
immunometabolic rewiring
pathogenic Th2 cells
regulatory T cells
tezepelumab
TSLP
Journal
A
IF:
12
Papers:
9.3K
Citations:
2.6W
Organization
Cited Papers